| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
20,210,000 |
| Market
Cap: |
6.09(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3012 - $0.3012 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Capricor Therapeutics is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. Co.'s primary cell therapy technology, CAP-1002, is based on cardiosphere-derived cells, which has been shown in pre-clinical and clinical studies to exert potential immunomodulatory activity and is being investigated for its potential to modify the immune system's activity to encourage cellular regeneration. Co. is also developing therapeutics and vaccines for infectious diseases, monogenic diseases and other potential indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
22,993 |
25,493 |
| Total Buy Value |
$0 |
$0 |
$65,212 |
$74,535 |
| Total People Bought |
0 |
0 |
3 |
4 |
| Total Buy Transactions |
0 |
0 |
5 |
7 |
| Total Shares Sold |
0 |
0 |
0 |
63,762 |
| Total Sell Value |
$0 |
$0 |
$0 |
$949,416,648 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
4 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Musket David B |
|
– • – |
2022-06-29 |
4 |
S |
$3.77 |
$106,371 |
D/D |
(28,215) |
12,747 |
|
- |
|
| Musket David B |
|
– • – |
2022-06-27 |
4 |
S |
$4.44 |
$78,921 |
D/D |
(17,775) |
40,962 |
|
- |
|
| Avat Xavier |
CHIEF BUSINESS OFFICER |
• – – |
2022-05-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
500 |
|
- |
|
| Manzo Louis |
|
– • – |
2022-03-31 |
4 |
D |
$3.43 |
$38,790 |
D/D |
(11,309) |
16,595 |
|
- |
|
| Manzo Louis |
|
– • – |
2022-03-31 |
4 |
OE |
$1.39 |
$38,787 |
D/D |
27,904 |
27,904 |
|
- |
|
| Dunbar George W Jr |
|
– • – |
2022-03-29 |
4 |
D |
$3.41 |
$21,483 |
D/D |
(6,300) |
9,155 |
|
- |
|
| Dunbar George W Jr |
|
– • – |
2022-03-29 |
4 |
OE |
$1.39 |
$21,482 |
D/D |
15,455 |
15,455 |
|
- |
|
| Collier Earl M Jr |
|
– • – |
2022-03-08 |
4 |
OE |
$1.39 |
$21,482 |
D/D |
15,455 |
15,455 |
|
- |
|
| Litvack Frank |
|
– • – |
2022-01-03 |
4 |
D |
$3.18 |
$214,815 |
D/D |
(67,552) |
107,382 |
|
- |
|
| Litvack Frank |
|
– • – |
2022-01-03 |
4 |
OE |
$1.39 |
$214,815 |
D/D |
154,543 |
174,934 |
|
- |
|
| Musket David B |
|
– • – |
2021-12-27 |
4 |
OE |
$1.10 |
$43,913 |
D/D |
35,846 |
58,737 |
|
- |
|
| Manzo Louis |
Director |
– • – |
2020-09-24 |
4 |
OE |
$3.70 |
$30,706 |
D/D |
8,299 |
44,603 |
|
- |
|
| Marban Linda |
CHIEF EXECUTIVE OFFICER |
• • – |
2020-07-27 |
4 |
D |
$9.81 |
$153,546 |
D/D |
(15,652) |
46,715 |
|
- |
|
| Marban Linda |
CHIEF EXECUTIVE OFFICER |
• • – |
2020-07-27 |
4 |
OE |
$3.70 |
$153,539 |
D/D |
41,497 |
62,367 |
|
- |
|
| Manzo Louis |
Director |
– • – |
2019-12-17 |
4 |
A |
$0.00 |
$0 |
D/D |
20,391 |
36,304 |
|
- |
|
| Musket David B |
Director |
– • – |
2019-12-17 |
4 |
A |
$0.00 |
$0 |
D/D |
20,391 |
22,891 |
|
- |
|
| Litvack Frank |
Director |
– • – |
2019-12-17 |
4 |
A |
$0.00 |
$0 |
D/D |
20,391 |
20,391 |
|
- |
|
| Smith Rachel |
Vice President of R&D |
• – – |
2017-12-22 |
4 |
D |
$1.48 |
$3,321 |
D/D |
(2,244) |
18,504 |
|
- |
|
| Smith Rachel |
Vice President of R&D |
• – – |
2017-12-22 |
4 |
OE |
$0.16 |
$3,320 |
D/D |
20,748 |
20,748 |
|
- |
|
| Manzo Louis |
Director |
– • – |
2017-10-23 |
4 |
OE |
$0.16 |
$3,320 |
D/D |
20,748 |
159,132 |
|
- |
|
| Cedars Sinai Medical Center |
10% Owner |
– – • |
2017-05-09 |
4 |
B |
$3.10 |
$3,549,999 |
D/D |
1,145,161 |
4,049,959 |
2.45 |
- |
|
| Musket David B |
Director |
– • – |
2017-05-09 |
4 |
B |
$3.10 |
$77,500 |
D/D |
25,000 |
25,000 |
2.39 |
- |
|
| Manzo Louis |
Director |
– • – |
2017-05-09 |
4 |
B |
$3.10 |
$31,000 |
D/D |
10,000 |
138,384 |
2.39 |
- |
|
| Marban Eduardo |
10% Owner |
– – • |
2016-10-25 |
5 |
GD |
$0.00 |
$0 |
D/D |
65,000 |
3,108,354 |
|
- |
|
| Marban Linda |
Chief Executive Officer |
• • – |
2016-10-25 |
5 |
GD |
$0.00 |
$0 |
D/D |
65,000 |
208,709 |
|
- |
|
82 Records found
|
|
Page 2 of 4 |
|
|
